Nel nostro studio abbiamo dimostrato, in una ampia popolazione di soggetti, che la tecnologia del defibrillatore sottocutaneo è ugualmente sicura ed efficace nei pazienti sottoposti al primo impianto ed in quelli che hanno subito la rimozione di un defibrillatore transvenoso per una complicanza del sistema. Anzi, in questo secondo gruppo il defibrillatore sottocutaneo può rappresentare la migliore e talora unica strategia di trattamento alternativo della morte cardiaca improvvisa.
Gli sviluppi tecnologici futuri incrementeranno sicuramente gli ambiti di utilizzo di questa nuova tecnologia per la migliore cura dei nostri pazienti.
65
Bibliografia
1. Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death - Addenda. Eur Heart J. 2015;36(41):2793-2867. doi:10.1093/eurheartj/ehv316.
2. United Nations Economic Commission for Europe. UNECE statistical database. Available at http://w3.unece.org/pxweb.
3. Zipes D, Libby P, Bonow R, et al. A textbook of cardiovascular medicine. pp858. Philadelphia, WB Saunders. 2005.
4. Zipes DP, Camm AJ, Borggrefe M, al et. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. J Am Coll Cardiol. 2006;48(5):e247.
doi:10.1016/j.jacc.2006.07.010.
5. Crotti L, Schwartz PJ. Morte Cardiaca Improvvisa. In: Società Italiana di Cardiologia, editor. Manuale di malattie cardiovascolari; 2013.
6. Maron BJ. Sudden death in young athletes. N Engl J Med. 2003;349(11):1064- 1075. doi:10.1056/NEJMra022783.
7. Obeyesekere M, Gula LJ, Skanes AC, Leong-Sit P, Klein GJ. Risk of sudden death in wolff-parkinson-white syndrome: How high is the risk? Circulation. 2012;125(5):659-660. doi:10.1161/CIRCULATIONAHA.111.085159. 8. Munger TM, Packer DL, Hammill SC, et al. A population study of the natural
history of Wolff-Parkinson-White syndrome in Olmsted County, Minnesota, 1953-1989. Circulation. 1993;87(3):866-873. doi:10.1161/01.CIR.87.3.866. 9. Acca E, Gorenek B. Cardiac arrhythmias in acute coronary syndromes:
position paper from the joint EHRA, ACCA, and EAPCI task force. EuroIntervention . 2014;10:2-20. doi:10.4244/EIJY14M08_19.
66
10. Myerburg RJ, Kessler KM, Castellanos A. Sudden cardiac death. Structure, function, and time-dependence of risk. Circulation. 1992;85(1 Suppl):2-10. 11. Lloyd-Jones DM, Wilson PWF, Larson MG, et al. Framingham risk score and
prediction of lifetime risk for coronary heart disease. Am J Cardiol. 2004;94(1):20-24. doi:10.1016/j.amjcard.2004.03.023.
12. CAST Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321(6):406-412.
doi:10.1056/NEJM198908103210629.
13. Huikuri H V., Castellanos A, Myerburg RJ. Sudden Death Due to Cardiac Arrhythmias. N Engl J Med. 2001;345(20):1473-1482.
doi:10.1056/NEJMra000650.
14. Part 4: The automated external defibrillator: Key link in the chain of survival. Resuscitation. 2000;46(1-3):73-91. doi:10.1016/S0300-9572(00)00272-0. 15. De Vreede-Swagemakers JJM, Gorgels APM, Dubois-Arbouw WI, et al. Out-
of-hospital cardiac arrest in the 1990s: A population-based study in the Maastricht area on incidence, characteristics and survival. J Am Coll Cardiol. 1997;30(6):1500-1505. doi:10.1016/S0735-1097(97)00355-0.
16. Reddy VY, Reynolds MR, Neuzil P, et al. Prophylactic Catheter Ablation for the Prevention of Defibrillator Therapy. N Engl J Med. 2007;357(26):2657- 2665. doi:10.1056/NEJMoa065457.
17. Standby automatic defibrillator. An approach to prevention of sudden coronary death. Mirowski M, Mower MM, Staewen WS, Tabatznik B, Mendeloff AI.Arch Intern Med. 1970 Jul;126(1):158-61.
18. Mirowski M, Reid P, Mower M, Watkins L. Termination of malignant ventricular arrhythmias with an implanted automatic defribillator in human beings. N Engl J Med. 1980;303(6):322-324.
67
19. Klein HU, Inama G. Implantable defibrillators: 30 years of history. G Ital Cardiol. 2010;11(10 Suppl 1):48S-52S.
20. Ezekowitz JA, Rowe BH, Dryden DM, et al. Systematic review: Implantable cardioverter defibrillators for adults with left ventricular systolic dysfunction. Ann Intern Med. 2007;147(4):251-262. doi:10.7326/0003-4819-147-4-
200708210-00007.
21. Kleemann T, Becker T, Doenges K, Vater M, Senges J, Schneider S, Saggau W, Weisse U, Seidl K. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of 10 years.
Circulation. 2007;115:2474 –2480.
22. Stephenson EA, Batra AS, Knilans TK, et al. A multicenter experience with novel implantable cardioverter defibrillator configurations in the pediatric and congenital heart disease population. J Cardiovasc Electrophysiol.
2006;17(1):41-46. doi:10.1111/j.1540-8167.2005.00271.x.
23. Zuber M, Huber P, Fricker U, Buser P, Jäger K. Assessment of the subclavian vein in patients with transvenous pacemaker leads. PACE - Pacing Clin Electrophysiol. 1998;21(12):2621-2630. doi:10.1111/j.1540-
8159.1998.tb00039.x.
24. Sandoe JAT, Barlow G, Chambers JB, et al. Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. J Antimicrob Chemother. 2015;70(2):325-359.
doi:10.1093/jac/dku383.
25. Tarakji KG, Chan EJ, Cantillon DJ, et al. Cardiac implantable electronic device infections: Presentation, management, and patient outcomes. Hear Rhythm. 2010;7(8):1043-1047. doi:10.1016/j.hrthm.2010.05.016.
26. Rohacek M, Baddour LM. Cardiovascular implantable electronic device infections: Associated risk factors and prevention. Swiss Med Wkly. 2015;145. doi:10.4414/smw.2015.14157.
68
27. Bennett JE, Dolin R, Blaser MJ. Basic Principles in the Diagnosis and
Management of Infectious Diseases. In: Principles and Practice of Infectious Diseases. ; 2014:358-376. doi:10.1016/B978-0-443-06839-3.00276-9. 28. Høiby N, Bjarnsholt T, Moser C, et al. ESCMID* guideline for the diagnosis
and treatment of biofilm infections 2014. Clin Microbiol Infect. 2015;21(S1):S1-S25. doi:10.1016/j.cmi.2014.10.024.
29. Esteban J, Molina-Manso D, Spiliopoulou I, et al. Biofilm development by clinical isolates of Staphylococcus spp. from retrieved orthopedic prostheses. Acta Orthop. 2010;81(6):674-679. doi:10.3109/17453674.2010.537810. 30. Bongiorni MG, Cori A Di, Cardiovascolari M. InfEzIonE dEl PACEMAKER
E dEll ’ ICd : un PRoblEMA In EsPAnsIonE ? :145-150.
31. Sohail MR, Uslan DZ, Khan AH, et al. Risk factor analysis of permanent pacemaker infection. Clin Infect Dis. 2007;45(2):166-173.
doi:10.1086/518889.
32. Massoure PL, Reuter S, Lafitte S, et al. Pacemaker endocarditis: Clinical features and management of 60 consecutive cases. PACE - Pacing Clin Electrophysiol. 2007;30(1):12-19. doi:10.1111/j.1540-8159.2007.00574.x. 33. Bongiorni MG, Tascini C, Tagliaferri E, et al. Microbiology of cardiac
implantable electronic device infections. Europace. 2012;14(9):1334-1339. doi:10.1093/europace/eus044.
34. Calvagna GM, Mangano AA, Evola R. Infezioni sulle estremità distali degli elettrocateteri da stimolazione cardiaca permanente rimossi. 2008;11:14-17. 35. Chamis AL, Peterson GE, Cabell CH, et al. Staphylococcus aureus bacteremia
in patients with permanent pacemakers or implantable cardioverter- defibrillators. Circulation. 2001;104(1524-4539 (Electronic)):1029-1033. doi:10.1161/hc3401.095097.
36. Klug D, Lacroix D, Savoye C, et al. Systemic Infection Related to
69
Circulation. 1997;95(8):2098-2107. doi:10.1161/01.CIR.95.8.2098. 37. Habib G, Lancellotti P, Antunes MJ, et al. 2015 ESC Guidelines for the
management of infective endocarditis. Eur Heart J. 2015;36(44):3075-3123. doi:10.1093/eurheartj/ehv319.
38. Murray P, Baron EJ, Pfaller M, et al. Manual of clinical microbiology, vol. 1. Washington, DC: American Society for Clinical Microbiology. 2003.
39. Wilkoff BL, Love CJ, Byrd CL, et al. Transvenous Lead Extraction: Heart Rhythm Society Expert Consensus on Facilities, Training, Indications, and Patient Management. This document was endorsed by the American Heart Association (AHA). Hear Rhythm. 2009;6(7):1085-1104.
doi:10.1016/j.hrthm.2009.05.020.
40. Uslan DZ, Dowsley TF, Sohail MR, et al. Cardiovascular implantable
electronic device infection in patients with staphylococcus aureus bacteremia. PACE - Pacing Clin Electrophysiol. 2010;33(4):407-413. doi:10.1111/j.1540- 8159.2009.02565.x.
41. Le Dolley Y, Thuny F, Mancini J, et al. Diagnosis of cardiac device-related infective endocarditis after device removal. JACC Cardiovasc Imaging. 2010;3(7):673-681. doi:10.1016/j.jcmg.2009.12.016.
42. Nagpal A, Baddour LM, Sohail MR. Microbiology and pathogenesis of cardiovascular implantable electronic device infections. Circ Arrhythmia Electrophysiol. 2012;5(2):433-441. doi:10.1161/CIRCEP.111.962753. 43. Durante-Mangoni E, Mattucci I, Agrusta F, Tripodi MF, Utili R. Current
trends in the management of cardiac implantable electronic device (CIED) infections. Intern Emerg Med. 2013;8(6):465-476. doi:10.1007/s11739-012- 0797-6.
44. Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009). Eur Heart J. 2009;30(19):2369-2413. doi:10.1093/eurheartj/ehp285.
70
45. Belesiotou E, Perivolioti E, Rouska E, et al. Infections Involving Cardiac Implantable Electronic Devices. Hosp Chronicles. 2014;9(1 Sup):103-106. 46. Sohail MR, Uslan DZ, Khan AH, et al. Infective Endocarditis Complicating
Permanent Pacemaker and Implantable Cardioverter-Defibrillator Infection. Mayo Clin Proc. 2008;83(1):46-53. doi:10.4065/83.1.46.
47. Le KY, Sohail MR, Friedman PA, et al. Impact of timing of device removal on mortality in patients with cardiovascular implantable electronic device infections. Hear Rhythm. 2011;8(11):1678-1685.
doi:10.1016/j.hrthm.2011.05.015.
48. Borek PP, Wilkoff BL. Pacemaker and ICD leads: Strategies for long-term management. J Interv Card Electrophysiol. 2008;23(1):59-72.
doi:10.1007/s10840-008-9249-7.
49. Varma N, Sellke FW, Epstein LM. Chronic atrial lead explantation using a staged percutaneous laser and open surgical approach. PACE - Pacing Clin Electrophysiol. 1998;21(7):1483-1485. doi:10.1111/j.1540-
8159.1998.tb00223.x.
50. CL B, BL W, CJ L, TD S, Reiser C. Clinical study of the laser sheath for lead extraction: the total experience in the United States. Pacing Clin
Electrophysiol. 2002;25(5):804-808.
51. Bongiorni MG, Soldati E, Zucchelli G, et al. Transvenous removal of pacing and implantable cardiac defibrillating leads using single sheath mechanical dilatation and multiple venous approaches: High success rate and safety in more than 2000 leads. Eur Heart J. 2008;29(23):2886-2893.
doi:10.1093/eurheartj/ehn461.
52. Bardy GH, Smith WM, Hood MA, et al. An Entirely Subcutaneous
Implantable Cardioverter–Defibrillator. N Engl J Med. 2010;363(1):36-44. doi:10.1056/NEJMoa0909545.
71
Circ Arrhythmia Electrophysiol. 2012;5(3):587-593. doi:10.1161/CIRCEP.111.964676.
54. Randles DA, Hawkins NM, Shaw M, Patwala AY, Pettit SJ, Wright DJ. How many patients fulfil the surface electrocardiogram criteria for subcutaneous implantable cardioverter-defibrillator implantation? Europace.
2014;16(7):1015-1021. doi:10.1093/europace/eut370.
55. Boston Scientific. Sq-Rx ® Pulse Generator a Component of the S-Icd System User ’ S Manual. In: ; 2008:1-40.
56. Nishii N, Tachibana M, Morimoto Y, et al. Initial experience with the subcutaneous implantable cardioverter-defibrillator in a single Japanese center. J Arrhythmia. 2017;33(4):338-341. doi:10.1016/j.joa.2017.02.004. 57. Boston Scientific. Emblem S-ICD System product details. Available at:
www.bostonscientific. com/en-US/products/defibrillators/emblem-s- icdsystem. html Accessed November 16, 2015.
58. Gold MR, Aasbo JD, El-Chami MF, et al. Subcutaneous implantable cardioverter-defibrillator Post-Approval Study: Clinical characteristics and perioperative results. Heart Rhythm. 2017.
59. Burke MC, Gold MR, Knight BP, et al. Safety and Efficacy of the Totally Subcutaneous Implantable Defibrillator. J Am Coll Cardiol.
2015;65(16):1605-1615. doi:10.1016/j.jacc.2015.02.047.
60. Burke MC, Gold MR, Knight BP, et al. Safety and efficacy of the totally subcutaneous implantable defibrillator: 2-year results from a pooled analysis of the IDE study and EFFORTLESS registry. J Am Coll Cardiol.
2015;65(16):1605-1615. doi:10.1016/j.jacc.2015.02.047.
61. Zeb M, Curzen N, Allavatam V, et al. Sensitivity and specificity of the
subcutaneous implantable cardioverter defibrillator pre-implant screening tool. Int J Cardiol. 2015;195:205-209. doi:10.1016/j.ijcard.2015.05.082.
72
totally subcutaneous implantable defibrillator: Early results from the EFFORTLESS S-ICD registry. Eur Heart J. 2014;35(25):1657-1665. doi:10.1093/eurheartj/ehu112.
63. Lewis GF, Gold MR. Safety and Efficacy of the Subcutaneous Implantable Defibrillator. J Am Coll Cardiol. 2016;67(4):445-454.
doi:10.1016/j.jacc.2015.11.026.
64. Jarman JWE, Todd DM. United Kingdom national experience of entirely subcutaneous implantable cardioverter-defibrillator technology: Important lessons to learn. Europace. 2013;15(8):1158-1165.
doi:10.1093/europace/eut016.
65. Moss AJ, Schuger C, Beck CA, et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. N Engl J Med. 2012;367(24):2275- 2283. doi:10.1056/NEJMoa1211107.
66. Dabiri Abkenari L, Theuns DAMJ, Valk SDA, et al. Clinical experience with a novel subcutaneous implantable defibrillator system in a single center. Clin Res Cardiol. 2011;100(9):737-744. doi:10.1007/s00392-011-0303-6.
67. Aydin A, Hartel F, Schlüter M, et al. Shock efficacy of subcutaneous
implantable cardioverter-defibrillator for prevention of sudden cardiac death: Initial multicenter experience. Circ Arrhythmia Electrophysiol. 2012;5(5):913- 919. doi:10.1161/CIRCEP.112.973339.
68. Olde Nordkamp LRA, Dabiri Abkenari L, Boersma LVA, et al. The entirely subcutaneous implantable cardioverter-defibrillator: Initial clinical experience in a large Dutch cohort. J Am Coll Cardiol. 2012;60(19):1933-1939.
doi:10.1016/j.jacc.2012.06.053.
69. Köbe J, Reinke F, Meyer C, et al. Implantation and follow-up of totally subcutaneous versus conventional implantable cardioverter-defibrillators: A multicenter case-control study. Hear Rhythm. 2013;10(1):29-36.
73
70. Weiss R, Knight BP, Gold MR, et al. Safety and efficacy of a totally subcutaneous implantable-cardioverter defibrillator. Circulation. 2013;128(9):944-953. doi:10.1161/CIRCULATIONAHA.113.003042. 71. Boersma L, Barr C, Knops R, et al. Implant and Midterm Outcomes of the
Subcutaneous Implantable Cardioverter-Defibrillator Registry: The EFFORTLESS Study. J Am Coll Cardiol. 2017;70(7):830-841. doi:10.1016/j.jacc.2017.06.040.
74
Sitografia
http://www.sicardiologia.it/Sito/ https://www.escardio.org/